Giovanni Pagano Selected Research

diepoxybutane

1/2021	Re-definition and supporting evidence toward Fanconi Anemia as a mitochondrial disease: Prospects for new design in clinical management.
7/2015	Fanconi anemia (FA) and crosslinker sensitivity: Re-appraising the origins of FA definition.
11/2003	Oxidative stress-related mechanisms are associated with xenobiotics exerting excess toxicity to Fanconi anemia cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Giovanni Pagano Research Topics

Disease

11	Mitochondrial Diseases (Mitochondrial Disease) 12/2021 - 01/2012
5	Neoplasms (Cancer) 01/2021 - 02/2008
4	Fanconi Anemia (Fanconi's Anemia) 07/2015 - 11/2003
3	Ataxia Telangiectasia (Louis Bar Syndrome) 01/2014 - 06/2007
2	Inflammation (Inflammations) 02/2021 - 08/2013
2	Disease Progression 01/2021 - 01/2020
2	Chromosome Aberrations (Chromosome Abnormalities) 01/2021 - 12/2019
2	Inborn Genetic Diseases (Disease, Hereditary) 01/2021 - 02/2008
2	Werner Syndrome (Werner's Syndrome) 01/2014 - 02/2008
2	Bloom Syndrome 02/2008 - 10/2007
2	Down Syndrome (Down's Syndrome) 02/2008 - 08/2006
1	Retinitis Pigmentosa (Pigmentary Retinopathy) 12/2021
1	Photophobia (Light Sensitivity) 12/2021
1	Hyperpigmentation 12/2021
1	Blindness (Hysterical Blindness) 12/2021
1	Carcinogenesis 10/2021
1	Sepsis (Septicemia) 02/2021
1	Pneumonia (Pneumonitis) 02/2021
1	COVID-19 02/2021
1	Friedreich Ataxia (Friedreich's Ataxia) 01/2021
1	DNA Repair-Deficiency Disorders (Chromosome Instability Syndromes) 07/2015
1	Congenital Bone Marrow Failure Syndromes 01/2014
1	Bone Marrow Failure Disorders 08/2013
1	Necrosis 01/2012
1	Xeroderma Pigmentosum (Kaposi's Disease) 02/2008
1	Ataxia (Dyssynergia) 02/2008

Drug/Important Bio-Agent (IBA)

7	milk-derived factorIBA 09/2020 - 02/2013
6	Reactive Oxygen Species (Oxygen Radicals)IBA 12/2021 - 08/2006
4	AntioxidantsIBA 12/2021 - 01/2012
3	coenzyme Q10 (CoQ10)IBA 12/2021 - 01/2021
3	Mitomycin (Mitomycin-C)FDA LinkGeneric 01/2021 - 11/2003
3	diepoxybutaneIBA 01/2021 - 11/2003
2	Carnitine (L-Carnitine)FDA LinkGeneric 12/2021 - 01/2021
2	Thioctic Acid (Lipoic Acid)IBA 12/2021 - 01/2021
2	Biomarkers (Surrogate Marker)IBA 02/2021 - 10/2007
2	XenobioticsIBA 01/2021 - 11/2003
2	DNA (Deoxyribonucleic Acid)IBA 07/2015 - 01/2014
2	Glutathione (Reduced Glutathione)IBA 01/2012 - 06/2007
1	Retinaldehyde (Retinal)IBA 12/2021
1	purineIBA 10/2021
1	Biological ProductsIBA 02/2021
1	FrataxinIBA 01/2021
1	Fanconi Anemia Complementation Group G ProteinIBA 01/2021
1	IronIBA 01/2021
1	Polymethyl Methacrylate (Sol)IBA 12/2019
1	NitrogenIBA 07/2015
1	Fanconi Anemia Complementation Group ProteinsIBA 07/2015
1	RNA (Ribonucleic Acid)IBA 08/2013
1	Proteins (Proteins, Gene)FDA Link 08/2013
1	MetalsIBA 08/2013
1	CytokinesIBA 08/2013
1	tempolIBA 01/2012
1	Peroxidase (Myeloperoxidase)IBA 01/2012
1	Oxygen (Dioxygen)IBA 01/2012
1	Protein CIBA 01/2012
1	LuminolIBA 01/2012
1	CytochromesIBA 01/2012
1	Glutathione Disulfide (GSSG)FDA LinkGeneric 01/2012
1	ResveratrolIBA 01/2012
1	Cisplatin (Platino)FDA LinkGeneric 11/2003
1	Methoxsalen (Oxsoralen)FDA Link 11/2003

Therapy/Procedure

2	Therapeutics 02/2021 - 01/2021
2	Chemoprevention 11/2014 - 02/2013
1	Transplantation 01/2021